This is how JPMorgan’s new headquarters looks; here are the perks associated with the building to lure back reluctant employees
JPMorgan Chase’s new headquarters in Manhattan is designed to make the 5-day return-to-office mandate more enticing, with ...
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...
Immuneering announces clinical supply agreement with Regeneron
Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...
Commercial Observer6h
The Plan: New Fort Greene Condo Emphasizes Minimalist Design and High-Quality Sound
A new tower is rising in Fort Greene, and it might just win over audiophiles. In October 2023, developer Charney Companies ...
Brand-new and ‘built on spec’: Why one Durham office building has sat empty since 2022
In the Triangle, office vacancies are at record highs. Some buildings, like Roxboro at Venable Center in Durham, are sitting ...
How abandoned office buildings in L.A. could be transformed into $1,000 a month studio apartments
A new report from Gensler and the Pew Charitable Trust proposes converting old office buildings into SRO-style housing.
Bdcnetwork.com23h
Office-to-residential conversions hit record high in 2025
Office-to-residential conversions are climbing to new heights in the new year. According to a recent RentCafe report, a ...
Regeneron Is Playing Defense With Capital Allocation
Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...
archpaper1d
The largest office-to-residential conversion project in New York City to date by CetraRuddy readies to open
CetraRuddy, a New York office, was behind the largest office-to-residential conversion project in New York City to date. 25 ...
Le Lézard2d
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer
MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced positive updated data from its THIO-101 ...